S&P Futures
5,912.25 +6.25 (+0.11%) Dow Futures
43,569.00 +51.00 (+0.12%) Nasdaq Futures
20,511.50 +28.00 (+0.14%) Russell 2000 Futures
2,296.30 +5.10 (+0.22%) Crude Oil
69.32 +0.10 (+0.14%) Gold
2,742.80 +12.80 (+0.47%)
Crinetics Pharmaceuticals, Inc. (CRNX)
After hours:
| Previous Close | 58.92 |
| Open | 58.91 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 58.40 - 59.80 |
| 52 Week Range | 25.75 - 59.80 |
| Volume | |
| Avg. Volume | 676,351 |
| Market Cap | 5.32B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 2,838,484 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This transaction, executed at a price of $51.10 per share, marks a notable expansion in State Street Corp's holdings within the biotechnology sector. The addition of these shares has increased the firm's total stake in Crinetics Pharmaceuticals to a substantial 3.60% of its portfolio, reflecting a strategic move to bolster its presence in the biotech industry.
- TipRanks
Morning Movers: Arcadium Lithium surges after deal to be acquired
Check out this morning’s top movers from around Wall Street, compiled by The Fly. HIGHER – Arcadium Lithium (ALTM) up 30% after Rio Tinto (RIO) and the company announced a definitive agreement under which Rio Tinto will acquire Arcadium in an all-cash transaction for $5.85 per share Clearside Biomedical (CLSD) up 10% after announcing that the ODYSSEY Phase 2b clinical trial of CLS-AX, or axitinib injectable suspension, for the treatment of neovascular age-related macular degeneration achieved bo
